Expertise in
3
conditions

Dr. Amanda J. Redig

Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
16 Years of Experience
Expertise in
3
conditions
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amanda Redig is an Oncologist in Boston, Massachusetts. Dr. Redig has been practicing medicine for over 16 years is highly rated in 3 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 32 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2010
Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Gefitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

32 Total Publications

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 28, 2021
Similar Doctors
Expertise in
28
conditions
Dr. Jeremy S. Abramson
Oncology | Hematology
Expertise in
28
conditions
Dr. Jeremy S. Abramson
Oncology | Hematology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Abramson is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
25
conditions
Dr. Caron A. Jacobson
Oncology | Hematology | Hematology Oncology
Expertise in
25
conditions
Dr. Caron A. Jacobson
Oncology | Hematology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Caron Jacobson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Jacobson is highly rated in 25 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobson is currently accepting new patients.

Lori J. Wirth
Expertise in
24
conditions
Dr. Lori J. Wirth
Oncology
Expertise in
24
conditions
Dr. Lori J. Wirth
Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lori Wirth is an Oncologist in Boston, Massachusetts. Dr. Wirth is highly rated in 24 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, Tissue Biopsy, and Thyroidectomy. Dr. Wirth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Redig's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile